Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T

被引:89
|
作者
Choi, I-Y [1 ]
Lee, S-P
Denney, D. R. [2 ]
Lynch, S. G.
机构
[1] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Dept Neurol,Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA
[2] Univ Kansas, Dept Psychol, Lawrence, KS 66045 USA
关键词
chemical shift imaging; glutathione; human brain; in vivo; magnetic resonance; neurodegeneration; oxidative stress; secondary progressive multiple sclerosis; IN-VIVO; OXIDATIVE STRESS; NEURODEGENERATIVE DISORDERS; WHITE-MATTER; DISEASE; PATHOGENESIS; METABOLISM; DISABILITY; CREATINE; SYSTEM;
D O I
10.1177/1352458510384010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Disability levels for patients with secondary progressive multiple sclerosis (SPMS) often worsen despite a stable MRI T-2 lesion burden. The presence of oxidative stress in the absence of measurable inflammation could help explain this phenomenon. In this study, the assessment of an in vivo marker of oxidative stress, cerebral glutathione (GSH), using magnetic resonance chemical shift imaging (CSI) is described, and GSH levels were compared in patients with SPMS and healthy controls. Objective: To assess whether GSH, a key antioxidant in the brain, is lower in the SPMS patients compared to matched controls. Methods: Seventeen patients with SPMS (Expanded Disability Status Scale = 4.0-7.0; length of MS diagnosis 19.4 +/- 7 years) and 17 age- and gender-matched healthy controls were studied. GSH levels were measured in the fronto-parietal regions of the brain using a specially designed magnetic resonance spectroscopy technique, CSI of GSH, at 3T. Results: The levels of GSH were lower for SPMS patients than for controls, the largest reduction (18.5%) being in the frontal region (p=0.001). Conclusion: The lower GSH levels in these patients indicate the presence of oxidative stress in SPMS. This process could be at least partially responsible for ongoing functional decline in SPMS.
引用
收藏
页码:289 / 296
页数:8
相关论文
共 50 条
  • [31] Treatment with glatiramer acetate reduces T1 and T2-weighted magnetic resonance imaging activity in patients with clinically isolated syndrome suggestive of multiple sclerosis
    Rocca, Maria A.
    Comi, Giancarlo
    Carra, A.
    Fazekas, Franz
    Rieckmann, Peter
    Bajenaru, O.
    Hillert, J.
    Elovaara, I.
    Young, C.
    Wynn, D.
    King, J.
    Lubetzki, C.
    Hartung, H. P.
    Myhr, Kjell-Morten
    Espejo, Carmen
    Komoly, S.
    Filippi, Massimo
    MULTIPLE SCLEROSIS, 2008, 14 : S176 - S176
  • [32] Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
    Arnold, Douglas L.
    Piani-Meier, Daniela
    Bar-Or, Amit
    Benedict, Ralph H. B.
    Cree, Bruce A. C.
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Arnould, Sophie
    Dahlke, Frank
    Hach, Thomas
    Ritter, Shannon
    Karlsson, Goeril
    Kappos, Ludwig
    Fox, Robert J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1526 - 1540
  • [33] Effect of interferon-β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis:: Results of a European multicenter, randomized, double blind, placebo-controlled trial
    Miller, DH
    Molyneux, PD
    Barker, GJ
    MacManus, DG
    Moseley, IF
    Wagner, K
    ANNALS OF NEUROLOGY, 1999, 46 (06) : 850 - 859
  • [34] Infratentorial hypointense lesion volume on T1-weighted magnetic resonance imaging correlates with disability in patients with chronic cerebellar ataxia due to multiple sclerosis
    Hickman, SJ
    Brierley, CMH
    Silver, NC
    Moseley, IF
    Scolding, NJ
    Compston, DAS
    Miller, DH
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 187 (1-2) : 35 - 39
  • [35] Comparison of baseline magnetic resonance imaging burden of disease and proton density and T2-weighted lesion activity between patients with relapsing-remitting and secondary progressive multiple sclerosis at the time of entry into therapeutic trials.
    Zhao, GJ
    Li, DKB
    Cheng, Y
    Wang, XY
    Paty, DW
    ANNALS OF NEUROLOGY, 1999, 46 (03) : 472 - 472
  • [36] Neurochemical Profile of Patients With Type 1 Diabetes (T1D) During Hyperinsulinemic Euglycemia (EU) and Hypoglycemia (HG) as Measured by 1H - Magnetic Resonance Spectroscopy (MRS) at 7 Tesla
    Moheet, Amir
    Terpstra, Melissa
    Kumar, Anjali
    Eberly, Lynn E.
    Oez, Gulin
    Seaquist, Elizabeth
    DIABETES, 2013, 62 : A66 - A67
  • [37] Multiple Sclerosis&IT Improved Detection of Active Cerebral Lesions With 3-Dimensional T1 Black-Blood Magnetic Resonance Imaging Compared With Conventional 3-Dimensional T1 GRE Imaging&IT
    Sommer, Nora N.
    Saam, Tobias
    Coppenrath, Eva
    Kooijman, Hendrik
    Kumpfel, Tania
    Patzig, Maximilian
    Beyer, Sebastian E.
    Sommer, Wieland H.
    Reiser, Maximilian F.
    Ertl-Wagner, Birgit
    Treitl, Karla M.
    INVESTIGATIVE RADIOLOGY, 2018, 53 (01) : 13 - 19
  • [38] Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis
    Valizadeh, Amir
    Moassefi, Mana
    Barati, Elham
    Ali Sahraian, Mohammad
    Aghajani, Faezeh
    Fattahi, Mohammad-Reza
    CNS NEUROSCIENCE & THERAPEUTICS, 2021, 27 (11) : 1268 - 1280
  • [39] Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study
    Stefano Bastianello
    Elisabetta Giugni
    Maria Pia Amato
    Maria-Rosalia Tola
    Maria Trojano
    Stefano Galletti
    Giacomo Luccichenti
    Mario Quarantelli
    Orietta Picconi
    Francesco Patti
    BMC Neurology, 11
  • [40] Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study
    Bastianello, Stefano
    Giugni, Elisabetta
    Amato, Maria Pia
    Tola, Maria-Rosalia
    Trojano, Maria
    Galletti, Stefano
    Luccichenti, Giacomo
    Quarantelli, Mario
    Picconi, Orietta
    Patti, Francesco
    BMC NEUROLOGY, 2011, 11